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Vaccines against S. aureus bovine mastitis are scarce and show limited protection only. All currently available vaccines are
applied via the parenteral (usually intramuscular) route. It is unknown, however, whether this route is the most suitable to
specifically increase intramammary immunity to combat S. aureus at the site of infection. Hence, in the present study,
immunization via mucosal (intranasal; IN), intramuscular (triangle of the neck; IM), intramammary (IMM) and subcutaneous
(suspensory ligament; SC) routes were analyzed for their effects on the quantity of the antibody responses in serum and
milk as well as the neutralizing capacity of the antibodies within serum. The experimental vaccine comprised the
recombinant S. aureus immune evasion proteins extracellular fibrinogen-binding protein (Efb) and the leukotoxin subunit
LukM in an oil-in-water adjuvant combined with a hydrogel and alginate. The highest titer increases for both Efb and
LukM specific IgG1 and IgG2 antibody levels in serum and milk were observed following SC/SC immunizations.
Furthermore, the harmful effects of Efb and leukotoxin LukMF’ on host-defense were neutralized by serum antibodies in a
route-dependent manner. SC/SC immunization resulted in a significant increase in the neutralizing capacity of serum
antibodies towards Efb and LukMF’, shown by increased phagocytosis of S. aureus and increased viability of bovine
leukocytes. Therefore, a SC immunization route should be considered when aiming to optimize humoral immunity
against S. aureus mastitis in cattle.Introduction
Infections with Staphylococci are common among humans
and animals [1-3]. In cattle subclinical intramammary infec-
tions with S. aureus are common. Infections may lead to
severe mastitis and/or chronic persistent infection with
detrimental effects for the cows’ well-being, lifespan and
milk production [4,5]. The current treatment of S. aureus
infections with antibiotics often fails to completely clear the
infection, due to specific cow or pathogen related risk
factors [6]. Ineffective treatment may result in increased
antibiotic resistance in S. aureus. Therefore, the avail-
ability of an effective vaccine would be of great value [7].
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against S. aureus mastitis are scarce and evaluation under
field conditions have shown to result in limited protection
only [8]. All current vaccines are applied parenterally in-
ducing a systemic immune reaction, which is reflected by
an increase in specific antibodies in serum [9]. To reach
the site of infection, antibodies induced by parenteral
immunization need to be translocated to the milk and
hence pass the blood-udder barrier, an effective, physio-
logical separation between the systemic circulation and
the udder tissue [10-13]. This does only occur once infec-
tion has been established, therefore the goal of prevent-
ing new intramammary infections has not been reached
so far [14,15]. To develop an effective vaccine against S.
aureus mastitis, it may be essential to increase intramam-
mary, rather than systemic, humoral immunity. To date,
little information is available regarding the impact of
immunization routes on humoral immune responses in
the bovine mammary gland [16,17].cle is distributed under the terms of the Creative Commons Attribution 4.0
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whether the udder is part of the mucosal immune system
or the skin immune system [18,19]. In addition, the envir-
onment of antigen uptake, processing and presentation
may influence the magnitude of the antibody response as
well as the neutralizing capacity of these antibodies. S.
aureus expresses and secretes many immune evasion
proteins [20]. Two of these proteins, extracellular
fibrinogen-binding protein (Efb) and the leukotoxin
subunit LukM, are suitable experimental antigens for
the assessment of antibody quantity and their neutral-
izing capacity after immunization via different routes.
Furthermore, both proteins are potential vaccine can-
didates since they are known to be involved in the
pathogenesis of many S. aureus strains [21-24]. Efb is
known to generate a capsule-like shield around the
surface of S. aureus through a dual interaction with
complement C3 and fibrinogen to mask surface-bound
C3b and antibodies thereby escaping recognition by
phagocytic cells like neutrophils [25]. LukM is the binding
subunit of the bi-component leukotoxin LukMF’, compe-
tent of killing bovine peripheral blood leukocytes (PBLs)
in a highly efficient manner [26,27]. Antibodies induced
by immunization may prevent the interaction of Efb with
C3, fibrinogen, or both, thereby preventing the formation
of a capsule-like shield. In addition, neutralization of
LukMF’ may be accomplished by antibodies blocking the
interaction of LukM with its target receptor on the surface
of neutrophils [28,29], or by antibodies blocking the
required interaction between LukM and LukF’, thereby
preventing pore formation [30]. Since it is thought that a
delay in neutrophil lysis will allow these cells to phagocyt-
ose S. aureus, increased levels of neutralizing antibodies to
both Efb and LukM are likely to improve vaccine effi-
ciency [30,31].
The objective of this study was to analyze the impact
of vaccine administration via different routes on the
quantity of the antibody responses as well as the neutral-
izing capacity of these antibodies in dairy cattle using
Efb and LukM as vaccine antigens.
Materials and methods
Animals
Sixteen clinically healthy mid-lactation dairy cows of the
Holstein Frisian breed purchased in the Netherlands were
housed at the Faculty of Veterinary Medicine (Utrecht,
The Netherlands). After arrival, somatic cell counts (SCC)
were determined at cow level by a commercial milk quality
assurance laboratory (Qlip, Zutphen, The Netherlands).
Only cows with a SCC <100 000 cells/mL were enrolled
and were allowed an acclimatization period of two weeks
to get used to the daily routine before sampling and
immunization. Cows were fed a diet based on grass and
corn silage, beet pulp and concentrate for the entire studyperiod which was formulated to meet the dietary require-
ments for lactating dairy cows (Dutch feeding tables; [32]).
Concentrate was administered via an automated feeding
system and irregular concentrate uptake was monitored.
Cows were milked twice a day and milk yield was recorded
with an automated milk recording system. Following
immunization, cows were daily monitored for signs of gen-
eral and local reactions to the immunization by a veterinar-
ian. The injection site was palpated to detect any swelling
and painfulness. In cases where local reactions at the site
of injection were observed a clinical examination of the
cow was performed to identify general reactions. When
immunization related changes in the udder tissue were
detected, quarter level SCC was determined using the
California mastitis test. When abnormalities in the milk
were observed, bacterial culture was performed by plating
50 μL of milk onto sheep blood agar plates. After an
overnight incubation at 37 °C bacterial growth was deter-
mined. Bacteria were presumptively identified by colony
size, morphology, pigmentation and type of hemolysis.
The use of animals in this study was approved by the
Ethical Committee for Animal Experiments of the Utrecht
University (DEC2012.II.09.136) and conducted according to
national regulations.
Vaccine composition and recombinant proteins
The experimental vaccine consisted of an oil-in-water
adjuvant combined with an alginate hydrogel (proprietary
adjuvant, MSD-AH). As antigenic proteins, Efb and
LukM, were used (50 μg/dose each). Cows were immu-
nized with S. carnosus derived Efb and E. coli derived
LukM. S. carnosus derived Efb was also used for ELISAs,
while neutralization assays were performed with E. coli de-
rived Efb, LukM and LukF’. For expression in S. carnosus,
the gene encoding efb from the S. aureus Newbould305
strain (ATCC29740) was amplified by PCR and ligated into
a pXR100 derived vector. S. carnosus culture supernatant
was 0.2 μm filtered, analyzed on gel for Efb purity and con-
centration, and stored at −20 °C. For expression in E. coli,
Efb, LukM and LukF’ proteins were generated as described
previously [33,34]. Briefly, the efb gene of the S. aureus
Newman strain and the lukm and lukf gene sequences
of the S. aureus field isolate S1444 were amplified by
PCR and ligated into the pRSETB vector (Invitrogen).
The proteins were expressed with a six-residue N-terminal
HIS-tag and purified by nickel-chelating chromatography
(GE Healthcare) according to the manufacturer’s manual.
Purified proteins were dialyzed against PBS and stored
at −20 °C.
Immunization
Cows were randomly assigned to four groups and im-
munized twice (1 mL/dose) with a 6 weeks interval.
Immunizations were administered intranasal (IN/IN),
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intramammary (one dose per each of the four milked-out
quarters) followed by a subcutaneous booster close to the
suspensory ligament (IMM/SC), and subcutaneous with
both injections close to the suspensory ligament (SC/SC).
The rationale behind the IMM/SC route was that cells
primed in the mammary tissue would migrate to the local
lymph node and re-enter the mammary gland following a
booster immunization thereby enhancing the local immune
response. For intranasal administration, aerosolized inocu-
lums with a variable size were injected directly into the
nostril using a nasal spray pump. For intramuscular and
subcutaneous administrations 21G needles (BD Micro-
lance™, Broek op Langedijk, The Netherlands) were used.
For intramammary administrations a sterile plastic 5 mL-
syringe and individual plastic infusion cannulas (Bovivet
Animal Healthcare, Konannkunte, Banglore) were used.
Sampling and sample preparation
Blood, milk, saliva and nasal secretion samples were
collected at three time points: before immunization, 3
weeks after the priming immunization, and 2 weeks after
the booster immunization. Blood was collected from the
coccygeal vein using a sterile blood collection system
(BD Vacutainer, Beckton Dickinson B.V., Breda, The
Netherlands) and, after coagulation, centrifuged for
10 min at 1000 × g to collect serum. Milk samples, col-
lected before the morning milking, were centrifuged for
10 min at 1000 × g to obtain skimmed milk. Saliva and
nasal secretions were collected by inserting a tampon
into the cow’s mouth or nostril. Tampons were removed
after 1 min and transferred into a 20 mL syringe. To ex-
tract secretions, 4 mL of PBS (Lonza, Basel, Switzerland)
were added and 1–2 mL of secretion was extracted from
each tampon by compression within the syringe barrel. All
samples were stored at −20 °C.
ELISA
The presence of Efb and LukM specific IgG1, IgG2 and
IgA antibodies in serum, milk, saliva and nasal secretions
was determined by ELISA. Plates (NUNC MaxiSorp™,
eBioscience, Affymetrix, Santa Clara, USA) were coated
with 0.55 μg/mL Efb or 3 μg/mL LukM in 0.05 M sodium-
bicarbonate buffer. Samples and positive control serum
were tested in two-fold serial dilutions. An in-house nega-
tive control serum was taken along in eightfold. As second-
ary antibodies, horseradish-peroxidase-conjugated sheep α
bovine IgG1, IgG2 and IgA (Bethyl Laboratories, Inc.,
Montgomery, USA) were used in 1:6000, 1:12 000 and
1:8000 dilutions for the Efb ELISAs, respectively. For the
LukM ELISAs these antibodies were used in 1:4000, 1:8000
and 1:5000 dilutions, respectively. Tetramethylbenzidine
was used as a substrate and reactions were stopped by
adding 4 N sulphuric acid. Extinctions (450 nm) weremeasured on a Tecan SUNRISE™ (Tecan Group Ltd.,
Männedorf, Switserland) spectrophotometer using the
XFluor4 Software Version V4.51-I4.
Efb neutralization assay
The neutralizing capacity of specific Efb antibodies in
serum was analyzed using a phagocytosis based assay
described previously [25]. In short, 2.5 μg Efb was
incubated with complement inactivated pre- or post-
immunization serum or negative control serum for 10 min
at room temperature (RT; 18–21 °C). Then, bovine lepiru-
din anti-coagulant plasma (5% final concentration; CSL
Behring GmbH, Marburg, Germany) and 0.6 × 107 CFU
FITC-labeled S. aureus KV27 were added, followed by an
incubation of 10 min at RT. Simultaneously, bovine PBLs
of a blood donor where freshly isolated by adding 10 mL
aquadest to 3 mL heparinized blood to lyse red blood cells.
Then, 37 mL of RPMI medium (Gibco®, Paisley, Scotland)
containing 0.05% human serum albumin was added
followed by centrifugation for 4 min at 300 × g. Cells were
washed twice and resuspended in medium. Leukocytes
(5 × 105 cells) were then added to the assay and phago-
cytosis was allowed for 15 min at 37 °C. The reaction
was stopped by 1% phosphate-buffered formaldehyde
fixation for 30 min at 4 °C and analyzed by flow
cytometry on a FACSCalibur (Beckton Dickinson B.V.,
Breda, The Netherlands). To determine changes in
phagocytosis as a result of antibody addition, cells were
gated based on their forward and side scatter. The
fluorescence of 10 000 gated neutrophils was measured
for each sample. Phagocytosis was expressed as the per-
centage of neutrophils with a fluorescence above baseline
(cells without fluorescent bacteria). Finally, phagocytosis
ratios post- and pre-immunization were determined. The
average ratio between post- and pre-immunization per cow
was calculated from four independent experiments using
blood from different donor cows.
LukM neutralization assay
Complement inactivated pre- and post-immunization sera
were analyzed for their ability to neutralize pore-
formation and cell lysis induced by LukMF’. Sera were
incubated with 33 nM LukMF’ for 30 min at RT and sub-
sequently with 5 × 106 bovine PBLs (isolated as described
above) in the presence of 1.8 μg/mL 4’, 6-diamidino-2-
phenulindole (DAPI). The final concentration of LukMF’
was 10 nM. DAPI fluorescence was measured in duplo for
30 min at 37 °C in a FLUOstar Omega microplate reader
(BMG Labtech GMBH, Ortenberg, Germany). The time
of lysis onset of the donor cells was defined as the time
when DAPI-fluorescence reached three times the standard
deviation of control samples that were incubated without
LukMF’. The average time of lysis onset was calculated
from three independent experiments.
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Antibody titers were determined using CaSpEx Software
AbendVertical version 0.11 V1 (MSD, Proprietary Software)
and defined as the dilution of the sample that would give
the same absorbance as the predefined cut-off. The cut-off
was defined as 2* average negative control. Data analysis
was performed in the SPSS statistical software package
(version 20; IBM SPSS statistics 20.0; IBM Corp., Armonk,
NY, USA). Data were checked for normality and Log2
transformed to achieve normality when necessary. Success
of randomization was checked by comparing initial group
antibody titers using an ANOVA with Bonferroni correc-
tion. Total titer increases and changes in phagocytic activity
were calculated by subtracting pre-immunization values of
post-booster values. Differences in total titer increase and
percentage phagocytosis between groups were analyzed
using the One-way ANOVA with Bonferroni correction.
Differences in lysis onset pre- and post-immunization in
the LukM neutralization assay were analyzed per group
using a repeated measures analysis with the lysis onset as
dependent variable. P-values below 0.05 were considered
significant. For graphical presentation of the data GraphPad
Prism software (Version 5; GraphPad Software Inc., La
Jolla, CA, USA) was used.
Results
Clinical observations
The median lactation of enrolled cows was 2 (min 1;
max 6). Cows produced on average 25.3 (SD ± 1.5) liters
of milk per day throughout the study. According to the
automated feeding system cows finished their daily
concentrate ration during the entire study period. A
small nodule at the site of injection developed in all IM
and SC immunized cows during the first 3 days post-
immunization. In one IMM immunized cow a hardened
quarter with an increased SCC was observed one day
following treatment. However, bacterial culture did notFigure 1 Pre-immunization titers of isotype specific antibodies direct
antibody titers in serum, milk, saliva and nasal secretion samples were meareveal the presence of any bacteria. IN immunized cows
did not display any symptoms at all. No systemic reac-
tions, changes in appetite or changes in milk production
were observed throughout the study. All nodules at the
application sites disappeared within 14 days following
immunizations.
Quantitative analyses of the antibody responses
Prior to immunization, in all cows Efb and LukM spe-
cific antibodies were detected in serum, milk, saliva and
nasal secretions, with the exception of Efb specific IgG1
and IgG2, and LukM specific IgA antibodies in milk
(Figure 1). The levels of these initial titers were not sig-
nificantly different between groups (Additional file 1).
Figure 2 shows the IgG1 and IgG2 antibody titer in-
creases in serum and milk. Efb specific antibody titers in
serum increased from 100 up to 2000 (IgG1) and from
1000 up to 15 000 (IgG2). LukM specific antibody titers
in serum increased from 300 up to 7000 (IgG1) and
from 6000 up to over 70 000 (IgG2). Milk titer increases
were minimal for Efb specific IgG1 and IgG2 antibodies,
whereas milk titer increases for LukM specific antibodies
ranges from 50 to 600 (IgG1) and from 20 up to 130
(IgG2). No significant route specific increases in total
antibody titers were observed over time. However, be-
tween routes statistically significant different titer in-
creases were observed. Following priming and booster
immunizations, the increase in Efb-specific IgG1 levels
in serum was significantly higher in IM/IM, IMM/SC
and SC/SC immunized animals than in IN/IN immu-
nized cows (p = 0.037, p = 0.001 and p = 0.000, respect-
ively; Figure 2A). The increase in Efb-specific IgG2
serum levels were higher in SC/SC immunized animals
compared to IN/IN and IM/IM immunized cows (both
p < 0.001; Figure 2B). Elevations in serum levels of
LukM-specific IgG1 were also significantly higher
following SC/SC immunizations compared to IN/INed against Efb and LukM. Initial Efb (A) and LukM (B) specific





Figure 2 IgG1 and IgG2 antibody titer increases in serum and milk. Isotype specific antibody titers in serum (A-D) and milk (E-H) following
IN/IN (●), IM/IM (■IMM/SC (▲) or SC/SC (▼) immunization with Efb (A-B, E-F) and LukM (C-D, G-H) were measured by ELISA. Results are
expressed as the mean per group ± SEM. Differences in total titer increases following prime plus booster immunizations were analyzed using the
One-way ANOVA. Letters indicate significant differences between IN/IN and IM/IM (a), IN/IN and IMM/SC (b), IN/IN and SC/SC (c), IM/IM and SC/SC
(d), and IMM/SC and SC/SC (e) immunization routes.
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specific increases in LukM-specific IgG2 serum levels
were not observed (Figure 2D). In milk, the increase
in Efb-specific IgG1 was higher following SC/SC
immunization than following IMM/SC immunization(p = 0.029; Figure 2E). These differences were not ob-
served for Efb-specific IgG2 levels (Figure 2F). LukM-
specific antibody titers in milk were only slightly affected by
immunization via the different administration routes with
the highest increases following SC/SC immunizations
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milk antibody levels compared to serum were only
moderate and pre- and post-immunization titers were
not statistically different.
In both milk and nasal secretions, Efb- and LukM-
specific IgA levels were not affected by immunization. IgA
levels in saliva were highly variable between cows and
both increases and decreases were observed within groups
in response to immunization (data not shown).
Serum and milk IgG1/IgG2 ratios did not change over
the course of the experiment for both Efb and LukM, indi-
cating that antibody increases following immunization with
the experimental vaccine were similar for IgG1 and IgG2.
Neutralizing capacity of the antibodies
Antibodies within serum were tested for their ability to
neutralize the inhibitory effects of Efb on phagocytosis.
Figure 3 shows the differences in phagocytosis ratios of
post- and pre-immunization serum. IM/IM and IMM/SC
immunizations did not result in increased phagocytosis
indicating that the induction of Efb neutralizing antibodies
was limited. Only one cow immunized via IN/IN adminis-
tration showed an increased percentage of phagocytosis
post-immunization. In contrast, all SC/SC immunized
animals showed an increase in neutralizing antibodies
post-immunization. The increase in the Efb neutralizing
capacity of serum antibodies was significantly higher
following SC/SC immunization than after IM/IM and
IMM/SC immunization (p = 0.015 for both groups).
Serum antibodies were also tested for their ability to
neutralize the effects of LukM on PBL lysis. Figure 4
shows that LukM specific antibodies in serum of SC/SC
immunized cows significantly blocked the pore forming
ability of LukMF’ when compared to pre-immunizationFigure 3 Efb neutralization assay. The presence of Efb neutralizing
antibodies in serum of cows from different immunization groups were
analyzed in an Efb neutralization assay. For each cow, the phagocytosis
ratio between post- and pre-immunization serum was calculated from
four independent neutralization experiments. Results are expressed as
the mean ratio per group ± SEM. Differences in neutralization ratios
between groups were calculated using the One-way ANOVA. *p< 0.05.serum (p = 0.009). LukM specific antibodies in serum
of IM/IM immunized cows also significantly decreased
the pore formation by LukMF’ compared to pre-im
munization serum (p = 0.012). However, the differences
in neutralization pre- and post-immunization were
limited compared to the increase observed in SC/SC
immunized cows. A trend in LukMF’ neutralization
was observed in serum of IMM/SC immunized cows
(p = 0.058), whereas no differences in neutralization of
LukMF’ were observed in serum of cows immunized
via the IN/IN route.
Discussion
The aim of this study was to assess whether the route of
immunization impacts the quantity of the antibody re-
sponse as well as the neutralizing capacity of these anti-
bodies, with an emphasis on intramammary immunity to
S. aureus.
Antibodies directed against Efb and LukM could be
detected in all cows prior to immunization. The induc-
tion of antibodies against S. aureus immune evasion pro-
teins following natural and experimentally induced acute
and chronic infections has previously been described in
human, mice, goats and cows [35-38]. The presence of
these antibodies demonstrates that S. aureus expresses
and secretes both proteins in vivo and that their pres-
ence can elicit an immune response. Since recurrent
infections with S. aureus frequently occur, it is unlikely
that the antibodies induced by natural infections are
protective against S. aureus. The lack of protection
(among other factors) may be due to insufficient antibody
levels at the site of infection. Even though high initial IgG1
and IgG2 levels were detected in pre-immunization serum
their levels in milk were remarkably lower. A lack of pro-
tection may also occur when naturally induced antibodies
do, for the main part, not target relevant (i.e. neutralizing)
epitopes. In this study, a rise in mainly serum, but also in
milk antibody levels following SC/SC immunizations was
observed. Furthermore, serum of SC/SC immunized cows
showed increased neutralization capacity in in vitro neutra-
lization assays. The increased antibody levels are likely to
contribute to the increased neutralization observed post
SC/SC immunization. These results are in line with previ-
ous studies where SC administration of recombinant Efb
or LukM resulted in the induction of antibodies with a
neutralizing effect on Efb and LukM in mice and rabbits
[22,23]. The neutralizing capacity of antibodies in milk
could not be measured since milk components interfere
with the fluorescence based assays and insufficient amounts
of milk were available for antibody isolation. As antibodies
which are translocated over the blood-udder barrier retain
their specificity [39,40], it is likely that the increased neu-
tralizing capacity of Efb and LukM specific antibodies is
also present in milk. The influence of immunizations on
Figure 4 LukMF’ neutralization assay. The presence of LukMF’ neutralizing antibodies in serum of cows from different immunization groups
were analyzed in a LukMF’ neutralization assay. For each group, the time of lysis onset between pre- (▲) and post- (■) immunization serum was
calculated. Results are expressed as time of lysis onset ± SEM of three independent neutralization experiments. Differences in the time of lysis
onset pre- and post-immunization within each immunization group were analyzed by repeated measures analysis. LukMF’ neutralization
post-immunization was significantly increased in cows immunized via SC/SC (p= 0.009) and IM/IM (p= 0.012) administration when compared to
pre- immunization.
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able. This might be due to the sample collection technique
used since the volumes of saliva and nasal secretions col-
lected in the tampons were not controlled during sampling.
This may have influenced the final antibody concentration
of the analyzed fluids. Therefore, a more standardized
method is required in order to analyze the IgA response
following immunization. Whether neutralizing antibodies
are beneficial to the clearance of S. aureus from the udder
at all has to be established in future research.
The immunization route and the applied adjuvant
determine the immunological environment antigens are
taken up and processed in [41]. Different responses may
be elicited when antigens are administrated in different
tissues [42,43]. Cytokines in the local environment influ-
ence the process of T cell stimulation by dendritic cells
and eventually determine the antibody isotype produced
by B-cells [40]. In this study, no shift in IgG1/IgG2 ratios
was observed following immunization, indicating a
similar production of both antibody isotypes regardless
of the immunization route. These findings correspond
with earlier studies where cows were immunized with an
S. aureus capsular polysaccharide type 5 conjugate in
combination with a mineral oil adjuvant or with a poly-
saccharide from Streptococcus agalactiae conjugated to
ovalbumin in Freund’s incomplete adjuvant [44-46].However, two other studies found a more pronounced
IgG2 response after immunization with an S. aureus
CP5-ovalbumin conjugate in Freund’s incomplete adju-
vant or with a killed S. aureus cell-toxoid vaccine using
dextran sulphate as an adjuvant [47,48]. Since alveolar
macrophages in the udder have been shown to lack IgG2
receptors [49] it has been speculated that, in order to
enhance local immunity, it is preferable to increase the
IgG1 titer in milk. IgG1 is selectively transported to the
mammary gland by the FcRn receptor [45]. During the
development of infection IgG2 leaks into the milk together
with other serum components [50]. Therefore, IgG2 is
thought to be more important in the second line of
defense. Notwithstanding, in the study presented here
immunization with antigens in a modified oil-in-water
adjuvant via different administration routes did re-
sulted in different levels and neutralizing capacity of
antibodies. Of all administration routes applied, subcuta-
neous tissue exhibited the best environment to evoke a re-
sponse against both Efb and LukM. Since all SC injections
were administered close to the suspensory ligament it
cannot be distinguished whether the subcutaneous route as
such was responsible for this beneficial effect or whether
it was the regional administration that influenced the
humoral response. However, previous studies did not ob-
serve differences in serum and milk antibody titer increases
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versus SC administration in the area of the supramammary
lymph node indicating that the administration route
might be more important than the location of adminis-
tration [51,52].
Intranasal, mucosal immunization resulted in a marginal
response only, indicating that this route is less suitable for
generating humoral protection against S. aureus immune
evasion proteins in the presence of the chosen adjuvant.
Although the classical IM route is widely used and
described to stimulate the humoral immune response in a
similar way as the SC route, in this study it only led to an
intermediate increase in antibody titers as did the com-
bined IMM/SC route [53,54].
In conclusion, this study showed that immunization
routes impact the antibody response induced against the
S. aureus immune evasion proteins Efb and LukM. A
subcutaneous immunization in the suspensory ligament
region resulted in higher antibody levels with increased
neutralization capacities when compared to the other
immunization routes.
Additional file
Additional file 1: Initial antibody titers per group. Prior to
immunization, Efb and LukM specific antibody titers in serum, milk, saliva
and nasal secretion samples were measured by ELISA. Results are
presented as the mean antibody titer per group (Log2) ± SEM. Success of
randomization was checked by comparing initial group antibody titers
using an ANOVA with Bonferroni correction. The levels of initial antibody
titers were not significantly different between groups.
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